Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas

Human Pathology

Volumn 38, Issue 12, 2007, Pages 1810-1818

  Kondo, Tetsuo ^a,c   Nakazawa, Tadao ^a   Murata, Shin ichi ^a   Kurebayashi, Junichi ^b   Ezzat, Shereen ^c   Asa, Sylvia L ^c   Katoh, Ryohei ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

B Raf; BRAF mutation; Immunohistochemistry; Thyroid carcinoma

Indexed keywords

B RAF KINASE; FIBROBLAST GROWTH FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL FUNCTION; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC DISORDER; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; POINT MUTATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICLE CELL; THYROID GLAND; THYROID HYPERPLASIA; TUMOR DIFFERENTIATION; UPREGULATION; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 36549090007     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.04.014     Document Type: Article

References (26)

1. Kondo T., Ezzat S., and Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6 (2006) 292-306
2. Sugg S.L., Ezzat S., Zheng L., et al. Oncogene profile of papillary thyroid carcinoma. Surgery 125 (1999) 46-52
3. Cheung C.C., Carydis B., Ezzat S., et al. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86 (2001) 2187-2190
4. Cohen Y., Xing M., Mambo E., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95 (2003) 625-627
5. Namba H., Nakashima M., Hayashi T., et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88 (2003) 4393-4397
6. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351 (2000) 289-305
7. Niihori T., Aoki Y., Narumi Y., et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38 (2006) 294-296
8. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
9. In: DeLellis R.A., Lloyd R.V., Heitz P.U., et al. (Eds). WHO classification of tumours. Pathology and genetics of tumours of endocrine organs (2004), IARC Press, Lyon (France) 49-123
10. Kurebayashi J., Tanaka K., Otsuki T., et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 85 (2000) 2889-2896
11. Kondo T., Nakamura N., Suzuki K., et al. Expression of human pendrin in diseased thyroids. J Histochem Cytochem 51 (2003) 167-173
12. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 (2005) 245-262
13. Trovisco V., Soares P., Soares R., et al. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 36 (2005) 694-697
14. Studer H., and Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia-a changing concept: a review focused on the thyroid gland. Endocr Rev 16 (1995) 411-426
15. Kawaoi A., Okano T., Nemoto N., et al. Simultaneous detection of thyroglobulin (Tg), thyroxine (T4), and Triiodothyronine (T3) in nontoxic thyroid tumors by the immunoperoxidase method. Am J Pathol 108 (1982) 39-49
16. Katoh R., Kawaoi A., Miyagi E., et al. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol 13 (2000) 570-576
17. Kondo T., Nakazawa T., Murata S.I., et al. Expression of CD73 and its ecto-5′-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology 48 (2006) 612-614
18. Mitsutake N., Miyagishi M., Mitsutake S., et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147 (2006) 1014-1019
19. Ouyang B., Knauf J.A., Smith E.P., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12 (2006) 1785-1793
20. Ciampi R., Zhu Z., and Nikiforov Y.E. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol 16 (2005) 99-105
21. Uribe P., Andrade L., and Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 126 (2006) 161-166
22. Tanami H., Imoto I., Hirasawa A., et al. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23 (2004) 8796-8804
23. Willmore-Payne C., Holden J.A., Hirschowitz S., et al. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37 (2006) 520-527
24. St Bernard R., Zheng L., Liu W., et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146 (2005) 1145-1153
25. Kimura E.T., Nikiforova M.N., Zhu Z., et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 (2003) 1454-1457
26. Fugazzola L., Puxeddu E., Avenia N., et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13 (2006) 455-464